Cancer of the colon: An update;Le cancer du colon : Mise au point

Bulletin du Cancer

Volumn 87, Issue SUPPL. 4, 2000, Pages 5-20

  Fabre, E ^a   Spano, J P ^a   Atlan, D ^a   Braud, A C ^a   Mitry, E ^a   Panis, Y ^a   Faivre, J ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BCG VACCINE; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MONOCLONAL MURIN; OXALIPLATIN; SULINDAC; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; COLON CARCINOMA; GENETIC ANALYSIS; HEREDITY; HUMAN; INFLAMMATION; PROGNOSIS; REVIEW; ADJUVANT CHEMOTHERAPY; COLON TUMOR; DIET; LIVER TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DIET; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PROGNOSIS;

EID: 0033789987     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (162)

1. Cancer du colon: Epidemiologie descriptive et groupes a risque eleve
2. L'apport des techniques moleculaires dans le depistage du cancer colorectal
3. Correlation between the location of germline mutations in the APC G and the number of colorectal polyps in familial adenomatous polyposis patients
4. Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients
5. Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history
6. Family history of colorectal tumours and implication for the adenoma-carcinoma sequence
7. A prospective study of family history and the risk of colorectal cancer
8. Alimentation et cancerogenese colorectale: Elements pour une prevention primaire
9. Physical activity, obesity and risk for colon cancer and adenoma in men
10. Increased risk of 'high risk' adenomas in overweight men
11. Insulin and colon cancer
12. The relationship between dietary fat intake and risk of colorectal cancer: Evidenced from the combined analysis of 13 case-control studies
13. Dietary fiber, vegetables, and colon cancer: Critical review and meta-analyses of the epidemiologic evidence
14. Dietary intake of fiber and decreased risk of cancer of colon and the rectum : Evidence from the combined analysis of 13 case-control studies
15. Dietary fibre and the risk of colorectal cancer and adenoma in women
16. Alcohol, tobacco and colorectal tumors : A multistep process
17. A meta-analysis of alcoholic beverage consumption in relation to risk of colorectal cancer
18. Chemoprevention of colorectal cancer: Recent results
19. Conference de consensus. Prevention, depistage et prise en charge des cancers du colon
20. Expression of prostaglandin G/H synthetase-1 and -2 proteine in human colon cancer
21. Sulindac for polyposis of the colon
22. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
23. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
24. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis
25. La consommation d'aspirine ou d'anti-inflammatoires non steroidiens diminue-t-elle le risque de cancer colique?
26. Colorectal cancer risk, chronic illness, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study
27. A hypothesis: Nonsteroidal anti-inflammatoty drugs reduce the incidence of large-bowel cancer
28. Effect of aspirin and nonsteroidal anti-inflammatory drugs on colorectal adenomas: Case control study of subjects participating in the Nottingham faecal occult blood sreening programme
29. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer
30. Nonsteroidal antiinflammatory drugs and colorectal cancer
31. Aspirin and the risk of colorectal cancer in women
32. Lowdose aspirin and incidence of colorectal tumors in a randomized trial
33. Risk and surveillance of individuals with colorectal polyps
34. A comparison of fecal occult-blood tests for colorectal-cancer screening
35. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention
36. Evaluation of new occult blood tests for detection of colorectal neoplasia
37. Can Hemoccult II replace colonoscopy in surveillance after radical surgery for colorectal cancercancer after polypectomy ?
38. Randomised, controlled trial of fecal occult blood screening for colorectal cancer
39. Repeated screening for colorectal cancer with fecal occult blood test
40. Controlled trial of faecal occult blood screening for colorectal cancer in Burgundy (France): Results of the first 9 years
41. Screening and rescreening for colorectal cancer: A controlled trial of fecal occult blood testing in 27,700 subjects
42. Participation in faecal occult blood screening for colorectal cancer in a well-defined French population: Results of five screening rounds from 1988 to 1996
43. Autoevaluation de la dynamique de distribution du test Hemoccult II en pratique de medecine generale dans le cadre d'un depistage de masse departemental
44. Le depistage de masse du cancer colorectal en France: Experience aupres de 165 000 personnes dans le Calvados
45. Mass screening for colorectal cancer: Statement of the European Group for Colorectal Cancer Screening
46. Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors. Science by mutant-allele-specific amplification (MASA)
47. Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR
48. Detection of oncogene mutation from neoplasic colonic cells exfoliated in feces
49. Detection of c-Kiras mutations in faecal samples from sporadic colorectal cancer patients
50. Identification of subjects at risk for colorectal carcinoma through a test basd on K-ras determination in the stool
51. Mutations of the p53 gene in the stool of patients with resectable colorectal cancer
52. Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer
53. Cancers colorectaux hereditaires sans polypose: Des genes au diagnostic
54. Clinicopathologic impact of colloid in colorectal carcinoma
55. Colorectal cancer
56. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases
57. Outcome-based equity in the treatment of colon cancer patients in Finland
58. Survival for colon and rectal cancer in a population-based cancer registry
59. A 5- to 21-year follow-up and analysis of 250 patients with rectal adenocarcinoma
60. Verification of a new clinicopathologic staging system for colorectal adenocarcinoma
61. Influence of socioeconomic status on prognosis of colorectal cancer
62. Les cancers du rectum et du colon dans le departement de la Cote-d'Or: Traitement, pronostic
63. Tumour site: A prognostic factor in colorectal cancer? A multivariate analysis
64. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group Experience
65. Clinicopathologically diagnosed residual tumor after resection for colorectal cancer: A 20year prospective study
66. Extended resections for primary colorectal carcinoma involving adjacent organs or structures
67. Lymph node recovery from colorectal resection specimens removed for adenocarcinoma: Trends over time and a recommendation for a minimum number of lymph nodes to be recovered
68. Facteurs pronostiques des adenocarcinomes colorectaux de stade B de Dukes
69. Venous invasion as a prognostic factor in colorectal cancer
70. Identification of occult micrometastases in pericolic lymph nodes of Dukes'B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49
71. Prognosis of node-positive colon cancer
72. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance
73. Prognostic factors in colonic cancer
74. Influence of mucinous components on survival in colorectal adenocarcinomas: A multivariate analysis
75. Tumour site: A prognostic factor in colorectal cancer? A multivariate analysis
76. Prognostic factors in Japanese patients with colorectal cancer: Significance of large bowel obstruction by univariate and multivariate analyses
77. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer
78. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NASBP clinical trials
79. p 53 in tumour pathology: Can we trust immunocytochemistry revisited?
80. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma
81. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis
82. p53 nuclear overexpression: An independent predictor of survival in lymph node-positive colorectal cancer patients
83. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma
84. The prognostic significance of direct extension of carcinoma of the colon and rectum
85. Areas of failure found at reoperation (second or symptomatic look) following 'curative surgery' for adenocarcinoma of the rectum: Clinicopathologic correlation and implications for adjuvant therapy
86. Colorectal cancer screening: Clinical guidelines and rationale
87. Barium enema versus colonoscopy for patients with polyps found during flexible sigmoidoscopy
88. The yield of flexible sigmoidoscopy and double-contrast barium enema in the diagnosis of neoplasmas in the large bowel in patients with a positive hemoccult test
89. Flexible sigmoidoscopy plus air contrast barium enema versus colonoscopy for suspected lower gastrointestinal bleeding
90. Bowel cleaning with polyethylen glycol electrolyte lavage solution
91. Effect of preoperative antibiotic regimen on development of infection after intestinal surgery: Prospective randomized double-blind trial
92. Principles of surgical resection: Influence of surgical technique on treatment outcome
93. Analysis of vascular anatomy and lymph node metastases warrants radical segmental bowel resection for colon cancer
94. The spread of rectal cancer and its effect on prognosis
95. Ovarian metastases from colorectal cancer
96. Avoiding diarrhea after subtotal colectomy with primary anastomis in the treatment of colon cancer
97. Presentation of cancer to hospital as 'acute abdominal pain'
98. Outcome after emergency surgery for cancer of the large intestine
99. Faut-il condamner la colostomie premiere dans les cancers coliques gauches en occlusion?
100. Surgical options for left-sided large bowel emergencies
101. Immediate colectomy and primary anastomosis for acute obstruction due to carcinoma of the left colon and rectum
102. Outcome after emergency surgery for cancer of the large intestine
103. Les perforations en peritoine libre d'origine neoplasique: Choix therapeutique
104. Peritonites primitives d'origine colique
105. Status of adjuvant therapy for colorectal cancer
106. Adjuvant therapy of colorectal cancer: Why we still don't know
107. The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer
108. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: A prospective randomized clinical trial
109. A meta-analysis of adjuvant therapy using oral fluoropyrimydines in patients with curatively resected colorectal carcinoma
110. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer
111. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic
112. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
113. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report
114. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer
115. Adjuvant 5FU plus levamisole improves survival in stage II and III colonic cancer, but not in rectal cancer. Interim analysis of The Netherlans Adjuvant Colorectal Cancer Project
116. Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer: A report of two cases and review of the literature. The INTACC. Intergruppo Nazionale Terpia Adiuvante Colon Carcinoma
117. FUFA increases disease-free survival in resected B2C colon cancer: Results of a prospective pooled analysis of 3 randomised trials
118. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (Impact) investigators
119. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer
120. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer
121. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03
122. Conference de consensus. Prevention, depistage et prise en charge des cancers du colon (texte court)
123. Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: Four-year results of INT-0089
124. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer
125. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04
126. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer
127. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
128. The tea leaves of small trials
129. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (Impact B2) Investigators
130. A randomized trial of intraportal versus systemic versus IP + SY adjuvant chemotherapy in patients with resected Dukes B-C colon carcinoma
131. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma
132. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma
133. Adjuvant therapy in large bowel adenocarcinoma: Long term results of a South West Oncology Group Study
134. Adjuvant chemoimmuno- and immunotherapy in Dukes' stage B2 and C colorectal carcinoma: A 7-year follow-up analysis
135. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer
136. Five-year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer
137. Adjuvant active specific immunotherapy for human colorectal cancer: 6,5-year median follow-up of a phase III prospectively randomized trial
138. Anatomie pathologique des metastases hepatiques des adenocarcinomes colorectaux
139. Epidemiologie des metastases hepatiques des cancers colorectaux
140. Resection of liver metastases: When is it worthwile?
141. Resection chirurgicale des metastases hepatiques
142. Surgical management of recurrence after resection of colorectal liver metastases
143. Utility of ultrasound in the surgery of liver tumours
144. Repeat hepatic resections for colorectal metastases
145. Advanced Colorectal Cancer Meta-analysis Project Modulation of 5fluorouracil by leucovorin in patients with advanced colorectal cancer Evidence in terms of response rate
146. Randomized trial comparing low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
147. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
148. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
149. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
150. Bimonthly acid folinic acid and 5FU bolus and continous infusion alone or with irinotecan for advanced colorectal cancer; preliminary results of a phase II randomized trial in southern Italy
151. Evaluation of oxaliplatin dose intensity with the bimonthly 48h leucovorin and 5-fluorouracil regimen (Folfox) in pretreated metastatic colorectal cancer
152. Evolution of the severe sensory neuropathy with oxaliplatin combined to bimonthly 48h leucovorin and 5-fluorouracil regimen (Folfox) in metastatic colorectal cancer
153. A phase III trial (SO14796) of xeloda (Capecitabine) in previously untreated advanced metastatic colorectal cancer
154. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma: A randomized trial
155. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer: A randomized trial
156. Hepatic arterial infusion of floxuridine in patients with liver metastases from coloractal carcinoma: Long-term results of a prospective randomized trial
157. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases
158. Le pronostic du cancer du colon dans les statistiques de population